A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy and Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer.

Trial Profile

A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy and Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Ontuxizumab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms MICRO
  • Sponsors Morphotek
  • Most Recent Events

    • 30 Oct 2017 Primary endpoint (Progression-free survival) has not been met, according to the results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 30 Oct 2017 Status changed from active no longer recruiting to discontinued, according to the results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 30 Oct 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top